Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma Non-small Cell Lung Cancer Stage IIIA Clear all
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery

NCT00662311
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
vorinostat, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Radiation Therapy Using 3-Dimensional Treatment Planning in Patients With Non-small Cell Lung Cancer

NCT00002484
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 13, 2026, 8:16 PM EDT
Completed No phase listed Observational

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

NCT00450567
View directory record Official record
Conditions
Lung Cancer
Interventions
computed tomography, positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 13, 2026, 8:16 PM EDT
Terminated Not applicable Interventional Results available

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

NCT00104728
View directory record Official record
Conditions
Lung Cancer
Interventions
ZD1839
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

NCT03456063
View directory record Official record
Conditions
Non-Small-Cell Lung
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Placebo Comparator, Nab-paclitaxel, Pemetrexed, Carboplatin, Cisplatin, Gemcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
24
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT01857271
View directory record Official record
Conditions
Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 13, 2026, 8:16 PM EDT
Recruiting Phase 2 Interventional

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

NCT07428044
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 13, 2026, 8:16 PM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00004253
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 13, 2026, 8:16 PM EDT
Completed No phase listed Observational

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00450281
View directory record Official record
Conditions
Lung Cancer
Interventions
chromogenic in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, study of socioeconomic and demographic variables, study of high risk factors
Genetic · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
405
States / cities
Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 279 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 13, 2026, 8:16 PM EDT
Completed No phase listed Observational

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease

NCT00754910
View directory record Official record
Conditions
Lung Cancer
Interventions
porfimer sodium, bronchoscopy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00043108
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

NCT02520778
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Navitoclax, Osimertinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
18
States / cities
Sacramento, California • Aurora, Colorado • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 13, 2026, 8:16 PM EDT
Active, not recruiting Not applicable Interventional

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

NCT04751747
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Computed Tomography, Contrast Agent
Procedure · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT02947386
View directory record Official record
Conditions
EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Nimotuzumab, Nivolumab
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Not applicable Interventional Results available

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

NCT02728596
View directory record Official record
Conditions
Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Breast Cancer, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIC Colorectal Cancer, Stage IIIA Breast Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
159
States / cities
Jonesboro, Arkansas • Martinez, California • Augusta, Georgia + 134 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

NCT01999881
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
exercise intervention, standard follow-up care, quality-of-life assessment, laboratory biomarker analysis
Behavioral · Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 13, 2026, 8:16 PM EDT
Completed No phase listed Observational

Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers

NCT00684801
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 2 Interventional

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

NCT00020202
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Interventions
FR901228
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00075426
View directory record Official record
Conditions
Lung Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00025480
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, tipifarnib, radiation therapy
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 13, 2026, 8:16 PM EDT
Terminated Phase 3 Interventional Results available

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00738881
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Pemetrexed Disodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
268
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Antioch, California + 176 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 13, 2026, 8:16 PM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00002577
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
224
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 13, 2026, 8:16 PM EDT
Active, not recruiting Phase 1 Interventional

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

NCT05166616
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Biopsy, Osimertinib, Triptolide Analog
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 13, 2026, 8:16 PM EDT